Rib metastasis is the spread of primary malignant tumors to the ribs via bone and is the most common malignant lesion of the ribs. It develops through hematogenous dissemination (including Batson's venous plexus). Most commonly from breast, lung, prostate, renal, and thyroid carcinomas. May present as lytic (bone-destructive), blastic (bone-forming), or mixed pattern: breast and lung are usually lytic, prostate is usually blastic, some breast and GI carcinomas produce mixed metastases. Clinically presents with localized pain, pathologic fracture, or incidental detection. Differentiation of metastasis vs primary bone tumor is critical in solitary rib lesions. Diagnosis is established by CT (cortical destruction, soft tissue mass), MRI (bone marrow involvement), and PET-CT (metabolic activity, whole-body screening). Biopsy is frequently required for definitive diagnosis.
Age Range
40-85
Peak Age
65
Gender
Equal
Prevalence
Common
Rib metastases develop when primary tumor cells reach the bone marrow via hematogenous route. Tumor cells engraft in the bone microenvironment according to the 'seed and soil' hypothesis — growth factors in bone marrow (TGF-beta, IGF, BMP) support tumor cell proliferation. In lytic metastases, tumor cells produce RANKL (receptor activator of nuclear factor kappa-B ligand) or stimulate osteoclast activation — increased osteoclastic bone resorption leads to destruction. In blastic metastases (prostate, some breast), tumor cells secrete osteoblast-stimulating factors like endothelin-1 and BMP — reactive new bone formation (woven bone) develops. The pathophysiological basis of imaging findings: in lytic metastases, bone mineral loss creates low-attenuation destruction areas; in blastic metastases, reactive new bone formation creates high-attenuation sclerotic areas. Soft tissue mass reflects extraosseous tumor growth beyond the cortex. On MRI, bone marrow replacement appears as low T1 signal (replacement of normal fatty marrow by tumor tissue).
Destruction of rib cortex with accompanying extraosseous soft tissue mass — cardinal CT finding of lytic metastasis. Demonstrates tumor invasion beyond bone into soft tissue.
On non-contrast CT, lytic rib metastasis appears as a low-attenuation area of destruction in the rib medulla and cortex. Cortical destruction is characteristic — cortical integrity is disrupted and tumor has formed an extraosseous soft tissue mass. Destruction pattern may be moth-eaten (irregular-marginated multiple small lytic areas) or permeative (infiltration in multiple thin channels). Soft tissue mass may involve pleural or chest wall soft tissue components. Lesions in multiple ribs strongly suggest metastatic disease.
Report Sentence
Lytic bone destruction with cortical disruption and ___ cm soft tissue mass is seen in the ___ rib, consistent with metastatic disease.
Blastic rib metastasis appears as a high-attenuation (sclerotic) lesion in the rib medulla. Bone density is markedly increased from normal (>500-1000 HU). Rib expansion is usually absent or minimal — unlike fibrous dysplasia. Most typical in prostate carcinoma, also seen in some breast carcinomas. In mixed metastases, lytic and blastic components coexist. Cortical thickening and irregular sclerosis may be seen.
Report Sentence
A sclerotic (blastic) lesion filling the medulla of the ___ rib is seen, consistent with metastasis in the context of known primary malignancy.
On T1-weighted images, rib metastasis shows hypointense signal due to replacement of normal fatty bone marrow (high T1 signal) by tumor tissue. This finding is present in both lytic and blastic metastases. Lesion margins are usually irregular. T1 hypointense lesions in multiple ribs strongly suggest widespread metastatic disease. In diffuse bone marrow infiltration, all bone marrow may show homogeneous low signal — analogous to 'super scan' phenomenon (on scintigraphy). On contrast-enhanced series, tumor tissue shows enhancement.
Report Sentence
Loss of normal bone marrow signal with hypointense signal is seen in the ___ rib on T1-weighted images, consistent with bone marrow replacement.
On PET-CT, rib metastasis appears as focal increased FDG uptake (SUVmax usually >5, variable depending on primary tumor type) in the rib lesion. Lytic metastases generally show high FDG avidity; blastic metastases (especially prostate) may show low-to-intermediate FDG uptake. PET-CT's advantage is simultaneous whole-body screening detecting other metastatic foci (bone, lung, liver, lymph nodes). In treatment response monitoring, SUVmax change reflects metabolic response. CT component provides anatomic localization and cortical assessment.
Report Sentence
Increased FDG uptake with SUVmax ___ is seen in the lytic/blastic lesion in the ___ rib on PET-CT, consistent with metabolically active metastatic disease.
On STIR sequence, rib metastasis shows markedly hyperintense signal — due to increased free water content and long T2 value of tumor tissue. While normal fatty bone marrow is suppressed (low signal) on STIR, tumor tissue gives bright signal — this contrast facilitates tumor detection. Soft tissue extension and surrounding tissue edema also show hyperintense signal. Diffusion restriction (tumor hypercellularity) may be seen on DWI. Whole-body MRI (whole-body DWI) is used as an alternative to PET-CT for bone metastasis screening.
Report Sentence
Markedly hyperintense bone marrow lesion with accompanying soft tissue extension is seen in the ___ rib on STIR sequence.
On bone scintigraphy, focal intense Tc-99m MDP uptake is seen in multiple ribs and other skeletal sites — classic finding of metastatic bone disease. Uptake mechanism differs in lytic and blastic metastases: in blastic metastases, increased osteoblastic activity directly provides intense uptake; in lytic metastases, reactive bone formation (osteoblastic response) leads to uptake. In some aggressive lytic metastases (renal, thyroid), osteoblastic response may be minimal — may appear as 'cold lesion' (photopenic). In widespread metastases, 'super scan' appearance may develop.
Report Sentence
Multiple foci of increased uptake consistent with metastatic bone disease are seen in multiple ribs and ___ regions on bone scintigraphy.
Criteria
Predominantly bone destructive, low-attenuation destruction areas, cortical disruption; typical in breast, lung, renal, thyroid carcinomas
Distinct Features
Moth-eaten/permeative destruction pattern, soft tissue mass common, high pathologic fracture risk; usually high FDG uptake on PET-CT
Criteria
Predominantly reactive bone formation, high-attenuation sclerotic areas; most typical in prostate carcinoma, some breast carcinomas
Distinct Features
Increased density, minimal rib expansion, low pathologic fracture risk; FDG uptake may be variable/low on PET-CT, NaF-PET more sensitive
Criteria
Lytic and blastic components coexist; in some breast, GI carcinomas, during post-treatment response
Distinct Features
Both destruction and sclerosis areas in same lesion, irregular margins; sclerosis of lytic lesions during treatment may indicate positive response
Distinguishing Feature
Fracture: clean cortical disruption line, displacement, callus (healing), trauma history; metastasis: moth-eaten destruction, soft tissue mass, known malignancy, multiple lesions
Distinguishing Feature
Plasmacytoma: expansile lytic, homogeneous enhancement, prominent rib expansion, solitary; metastasis: cortical destruction dominant, heterogeneous, usually multiple
Distinguishing Feature
Chondrosarcoma: ring-and-arc calcification (chondroid matrix), costochondral junction location, cartilage origin; metastasis: no ring-and-arc, any location, known primary tumor
Distinguishing Feature
Myeloma: punched-out lytic lesions (sharp borders, no sclerotic rim), diffuse osteopenia, positive serum/urine protein electrophoresis; metastasis: irregular-marginated lytic destruction, may have periosteal reaction, known primary tumor
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
3-monthRib metastasis is an indicator of systemic disease and requires multidisciplinary oncologic management. Biopsy is frequently required for definitive diagnosis in solitary rib lesions — especially when primary malignancy is unknown. Biopsy may not be needed in the context of known primary malignancy + multiple bone lesions. Treatment is determined by primary tumor type: systemic chemotherapy, hormonal therapy (breast/prostate), radiotherapy (pain control, pathologic fracture risk), bisphosphonates/denosumab (bone resorption inhibitor). Prophylactic stabilization should be considered for lesions at risk of pathologic fracture. Follow-up: treatment response assessment with 3-monthly CT/PET-CT.
Rib metastasis in the setting of known malignancy indicates advanced-stage disease (stage IV). Treatment is systemic (chemotherapy, hormonal therapy, immunotherapy) and palliative (radiotherapy — pain control). Prophylactic stabilization should be considered for lesions at risk of pathologic fracture. Biopsy for primary/metastatic differentiation is needed in solitary rib lesion. Serum protein electrophoresis and bone marrow biopsy are required when multiple myeloma is suspected.